SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD

Review checklist: Edward W. Brooke (HR-ML014)
All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments
Everything a reviewer needs to judge, gathered from the record. Release status: draft.
- 11judgment calls in the dossier
- 2protocol deviations
- 1orders and referrals without results in the record
- 0evidence items to check (retrospective or sensitive claims, unconfirmed diagnoses)
Review status
| Review | Status | Reviewer | Date | Notes |
|---|
| schema validation | not_started | | | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | | | Awaiting clinician review; check the omission of chemotherapy and radiation at 83, the tamoxifen monitoring, and the bone-health plan. |
| provenance review | not_started | | | Recent-death rule: only what Brooke said publicly (a 2003 CNN interview and Associated Press reports) and basic biographical facts are used. No physician of his made a public statement that was found. Statements about his relatives in the news reports are not used. |
| safe messaging review | not_started | | | Breast cancer in a man is described plainly, without any framing of it as embarrassing; no behavioral-health diagnosis; death recorded without detail. |
Judgment calls (dossier editorial resolutions)
- Recent-death rule. Brooke died in 2015. The case uses only what he made public himself (a live CNN interview in June 2003 and the Associated Press reports of the same week), basic biographical facts from the House of Representatives and the Congressional Record, and the cause of death given publicly by his former chief counsel. No physician of his made a public statement that was found. No medical records, accounts by relatives, or speculation about undisclosed conditions are used. His tumor size, grade, receptor status, node count, stage, examination findings, results, medicines, germline result, and preventive care are synthetic. The recent-death review rule applies.
- Men get breast cancer. The record states this plainly and treats his cancer as an ordinary diagnosis. His own public points (that he dismissed the symptom, that no doctor had ever examined his chest, that he had not known men could get it, and that men should not be “macho” about it) frame the teaching. Nothing in the record treats the diagnosis as embarrassing or unmanly.
- Relatives. The interview and the AP report give a relative’s role in his seeking care and a relative’s own health history. Neither is used, so that no decision, statement, or health fact is attributed to a real relative. The record has no family history entries. The spouse in the social history and in the advance care planning is not named. The letter for relatives after the germline result names no one.
- Operation. The AP report, citing his New York Times interview, says he had a double mastectomy. In the CNN interview he said he “had to be operated on” and that all the lymph nodes on his right side were removed. The two accounts do not conflict. The record codes a bilateral mastectomy with a right axillary dissection. The reason the left breast was also removed was not made public, so none is given. The pathology of the left breast is synthetic and benign.
- Index age. The modern episode presents Brooke at 83, about three and a half months after his operation. That is the earliest point the 2026 calendar allows without contradicting the documented September 2002 diagnosis. His public interview fixed his age as 83 at that time. The synthetic date of birth is October 26, 1942 (shift 23 years). The diagnostic imaging, biopsy, operation, and start of tamoxifen are dated September and October 2025 (true frame September and October 2002). The index visit on January 13, 2026 maps to January 13, 2003. The chronic-care visits on February 10, May 12, and August 11, 2026 map to the same days of 2003. The annual wellness visit on October 13, 2026 maps to October 13, 2003, when he was still 83. His public disclosure in June 2003 falls between the third and fourth visits, so the fourth visit and the wellness visit mention that he has begun speaking about breast cancer in men. Past medical history holds only the 2002 diagnosis and operation.
- Synthetic clinical picture. The right-sided cancer, the imaging and needle biopsy, the operation, and the nodal spread are from his public account. Everything else is synthetic and chosen to be typical of breast cancer in men (retroareolar, invasive ductal, strongly hormone receptor-positive, HER2-negative): a 1.8 cm grade 2 tumor with one of fourteen nodes involved (pT1c pN1a, stage IIA). Radiation and chemotherapy are recorded as not given after a decision at the other hospital. The consultant agrees, given his age and the low nodal burden. His actual treatment after surgery was not made public. Results are kept normal or mild (vitamin D 24 ng/mL, femoral neck T-score -1.2, PHQ-9 3) so that nothing reads as a claim about his undisclosed health.
- Germline result. Germline testing is offered and done, because the ASCO guideline calls for it in every man with breast cancer. The synthetic result is negative (no pathogenic variant). A negative result was chosen so that the record makes no claim about an inherited variant in him or his relatives. It is still a synthetic genetic result and is flagged for review.
- Annual wellness visit. A subsequent Medicare annual wellness visit (age 83, so `annual_wellness_subsequent`) was added on October 13, 2026 (true frame October 13, 2003). No sick visit was added: under the recent-death rule the case adds no synthetic illness episode. Judgment calls: (1) no alcohol and no tobacco follow his public description of himself; (2) colorectal screening and a statin for primary prevention were discussed and not recommended at his age; (3) advance care planning names an unnamed health care agent and records only general priorities, with no treatment preference; (4) the RSV and COVID-19 vaccines are left to the pharmacy and recorded as due.
- Focused visits. The three chronic-care follow-ups (four weeks, four months, and seven months after the first visit) are documented as focused visits on the ASCO male breast cancer guideline and the CMID breast cancer monograph. Each lists every item the protocol calls for at that point, with its interval and status. The four-week visit is the same day as the medical oncology consultation and the DXA scan. One protocol deviation is recorded instead of an invented result: the sexual side-effect question was not asked at the four-week visit. At the next visit he reported a mild fall in libido that he had not raised himself, with no effect on adherence, so no harm is judged to have resulted. The question was added to his visit checklist. Mammography and routine blood tests, tumor markers, and scans are recorded as not indicated, with the reason. The germline result is reported in prose because the oncology and genetics teams ordered and resulted it.
- Consultation. The medical oncology referral and the consultation by Mei-Ling Cho, MD (a fictional consultant), on the day of the four-week visit, are S. The consultant answers the five referral questions with what the record shows happened afterwards: tamoxifen 20 mg for an initial five years (not an aromatase inhibitor alone), no chemotherapy or radiation, a germline multigene panel with counseling and a letter for relatives, tamoxifen safety checks at every visit with the CYP2D6 inhibitors to avoid, surveillance by examination with no breast imaging after bilateral mastectomy, and vitamin D with DXA every two years. The examination is consistent with Dr. Bellamy’s same-day note. Under the recent-death rule, the consultant’s note records his wish to keep the diagnosis private, in line with his public account that he did so for several months.
- Not used. His later years, any account of his health after 2003, the relatives’ roles described in news reports, and his farm and travel are not used. His height is not recorded in a fetched source; the 183 cm in the record is synthetic. An NPR program on breast cancer in men from July 2003 could not be fetched.
Protocol deviations
Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.
| Visit | Measure | Interval | What happened |
|---|
2026-02-10 Progress note 02 (C-CDA) | Sexual side effects of tamoxifen (libido, erectile function) | Every visit on tamoxifen | Not asked today, a deviation from the protocol; the visit was taken up by the bone density and consultation results. To be asked at the next visit |
2026-05-12 Progress note 03 (C-CDA) | Sexual side effects missed at the last visit | Every visit on tamoxifen | Not asked at the previous visit, a deviation from the protocol. Asked today: a mild fall in libido that he had not raised himself and that has not affected his adherence, so no harm resulted. The question is now on his visit checklist, because men often do not mention these effects unless asked |
Orders and referrals without results in the record
| Visit | Type | Item | Status | Detail |
|---|
2026-02-10 Progress note 02 (C-CDA) | Laboratory | Germline multigene panel testing | Ordered | Blood sent today by medical oncology; genetic counseling before and after the result |
Evidence to check
Retrospective claims (R)
None.
Sensitive claims
None.
Diagnoses not confirmed
None.
Notes to read
Every note in the record, with its type. All clinical content is synthetic.
Abnormal results
| Date | Result | Value | Flag |
|---|
| 2026-01-13 | 25-hydroxyvitamin D | 24 ng/mL (low) | Low |
| 2026-02-10 | Femoral neck T-score (DXA) | -1.2 (low) | Low |